tetano
Editor, Senior Moderator
Expert Rev Vaccines. 2016 Apr 8. [Epub ahead of print]
[h=1]Progress in Developing Virus-like Particle Influenza Vaccines.[/h] Quan FS[SUP]1[/SUP], Lee YT[SUP]2[/SUP], Kim KH[SUP]2[/SUP], Kim MC[SUP]2,[/SUP][SUP]3[/SUP], Kang SM[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Recombinant vaccines based on virus-like particles (VLPs) or nanoparticles have been successful in their safety and efficacy in preclinical and clinical studies. The technology of expressing enveloped VLP vaccines has combined with molecular engineering of proteins in membrane-anchor and immunogenic forms mimicking the native conformation of surface proteins on the enveloped viruses. This review summarizes recent developments in influenza VLP vaccines against seasonal, pandemic, and avian influenza viruses from the perspective of use in humans. The immunogenicity and efficacies of influenza VLP vaccine in the homologous and cross-protection were reviewed. Discussions include limitations of current influenza vaccination strategies and future directions to confer broadly cross protective new influenza vaccines as well as vaccination.
[h=4]KEYWORDS:[/h] Influenza virus; Vaccines; Virus-like particles; cross protection; strain-specific protection
PMID: 27058302 [PubMed - as supplied by publisher]
[h=1]Progress in Developing Virus-like Particle Influenza Vaccines.[/h] Quan FS[SUP]1[/SUP], Lee YT[SUP]2[/SUP], Kim KH[SUP]2[/SUP], Kim MC[SUP]2,[/SUP][SUP]3[/SUP], Kang SM[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Recombinant vaccines based on virus-like particles (VLPs) or nanoparticles have been successful in their safety and efficacy in preclinical and clinical studies. The technology of expressing enveloped VLP vaccines has combined with molecular engineering of proteins in membrane-anchor and immunogenic forms mimicking the native conformation of surface proteins on the enveloped viruses. This review summarizes recent developments in influenza VLP vaccines against seasonal, pandemic, and avian influenza viruses from the perspective of use in humans. The immunogenicity and efficacies of influenza VLP vaccine in the homologous and cross-protection were reviewed. Discussions include limitations of current influenza vaccination strategies and future directions to confer broadly cross protective new influenza vaccines as well as vaccination.
[h=4]KEYWORDS:[/h] Influenza virus; Vaccines; Virus-like particles; cross protection; strain-specific protection
PMID: 27058302 [PubMed - as supplied by publisher]